Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) (Q102141449)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 November 2020

Language	Label	Description	Also known as
English	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)	scientific article published on 17 November 2020

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

1 reference

based on heuristic

inferred from title

Jennifer L Caswell

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Katherine Pogrebniak

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Christina Curtis

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Michael F Press

22

object named as

Michael F Press

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

1

object named as

Sara A Hurvitz

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Jason J Zoeller

4

object named as

Jason J Zoeller

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

25

object named as

Dennis J Slamon

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

author name string

Robert Dichmann

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Alejandra Perez

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Ravindranath Patel

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Lee Zehngebot

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Heather Allen

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Linda Bosserman

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Brian DiCarlo

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

April Kennedy

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Armando Giuliano

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Carmen Calfa

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

David Molthrop

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Aruna Mani

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Hsiao-Wang Chen

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Judy Dering

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Brad Adams

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Eran Kotler

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

publication date

17 November 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Nature Communications

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

5824

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

describes a project that uses

1 reference

Europe PubMed Central

22 June 2022

https://europepmc.org/article/PMC/7673127

based on heuristic

inferred from PubMed Central ID database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy as a platform for drug development and approval in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inferring tumour purity and stromal and immune cell admixture from expression data

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Molecular Signatures Database (MSigDB) hallmark gene set collection

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The immune system and response to HER2-targeted treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Robust enumeration of cell subsets from tissue expression profiles

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Widespread parainflammation in human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

limma powers differential expression analyses for RNA-sequencing and microarray studies

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of background correction methods for two-colour microarrays

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjusting batch effects in microarray expression data using empirical Bayes methods

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Absolute assignment of breast cancer intrinsic molecular subtype.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-19494-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/S41467-020-19494-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

2020NatCo..11.5824H

0 references

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33203854%20AND%20SRC:MED&resulttype=core&format=json

20 November 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q102141449&oldid=1939883495"